### Fall 2012 Meeting

**Thursday, November 1st, 2012**  
250 Massachusetts Ave., Auditorium  
Cambridge, MA

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:45</td>
<td>Registration, bagels, coffee</td>
</tr>
</tbody>
</table>
| 8:45-9:00| **Welcome and introduction**  
*Page Bouchard, DVM, DACVP – Global Head of Preclinical Safety, Novartis* |
| 9:00-9:45| **The Ophthalmic Examination in Safety Studies: Procedures, Normals, and Meaningful Findings**  
*Jay Fortner, DVM, DACLAM – Pfizer* |
| 9:45-10:30| **Maintaining Clinical Relevance in Ocular Toxicity Studies – Intervening Treatments & Incorporation of Clinical Technologies**  
*Brenda Smith, PhD – Alcon* |
| 10:30-11:00| Break                                                                |
| 11:00-11:45| **Understanding What We Cannot See – The Challenges of the Ocular PK of Biologics**  
*Mark Milton, PhD – Novartis* |
| 11:45-1:00| Lunch                                                                 |
| 1:00-1:45| **Ocular Pathology of Ocular Administration of Therapeutic Drugs and Devices**  
*Ken Schafer, DVM, DACVP – Vet Path Services* |
| 1:45-2:30| **Preclinical development of antisense oligonucleotides for ocular disease**  
*Husam Younis, PhD – Isis* |
| 2:30-3:00| Break                                                                  |
| 3:00-3:45| **MEK-Inhibitor Induced Retinopathy: Mechanistic Insights Acquired Through the Development of a Preclinical Model**  
*Stan Spence, PhD – Novartis* |
| 3:45-4:30| **IND-Enabling Studies of EBI-005: A Novel Protein IL-1 Receptor Inhibitor for Topical Treatment of Dry Eye Syndrome**  
*Eric Furfine, PhD – Eleven Biotherapeutics* |